BLUE - bluebird bio EV/EBITDA Multiple
Management at bluebird bio, Inc. (BLUE) demonstrates deep scientific expertise and data transparency, although sluggish sales growth is weighing on liquidity. The situation is further complicated by a funding shortage resulting from the colossal costs associated with bringing drugs to market. This chart on GURU.Markets shows the asset valuation (EV/EBITDA) is . The business of correcting genetic defects remains independent of GDP, relying instead on the critical necessity of therapy and insurance payouts.
Comprehensive metric breakdowns and analytics for bluebird bio (BLUE)
- current price and projected stock value:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio bluebird bio, Inc.|BLUE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Bluebird Bio|BLUE - Company Debts|Debts to Book Capitalization Bluebird Bio|BLUE - Long-Term Debt Volume|Company Short-Term Debt bluebird bio|Quick Liquidity Indicator bluebirdbio.com
- business earnings and investment ratios data:
BLUE - Final Profit|Projected Future Earnings bluebird bio, Inc.|BLUE - Business Payback Period|Future Price to Earnings Bluebird Bio|BLUE - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple bluebird bio Inc.|BLUE - Operating profit before deduction of amortization|Net earnings per share for the last 12 months bluebird bio|BLUE - Net earnings per share for the last four quarters|Quarterly EPS earnings growth bluebirdbio.com|BLUE - Earnings per share growth in current year|Net earnings per share growth forecast for next year bluebird bio, Inc.
- company sales and revenue statistics:
Summary company analytics:bluebirdbio.com BLUE
Monetizing unique gene therapies for patients with rare pathologies requires colossal expenditures, making the historical EV/EBITDA chart for bluebird bio, Inc. (BLUE) a key analytical tool. This indicator compares the total enterprise value, including net debt, with operating profit before depreciation and amortization. This allows investors to objectively assess the asset's value by eliminating the impact of tax regimes and debt loads on the actual efficiency of the business.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Sionna Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA (Taysha Gene Therapies) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO Inc - EV/EBITDA Multiple|Company Value to EBITDA Solid Corp|Ocugen (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pacific Biosciences|Enterprise Value to EBITDA Ratio BNTC|Enterprise Value to EBITDA Ratio Design Therapeutics Inc (DSGN)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Enterprise Value to EBITDA Ratio|KRRO: Enterprise Value to Operating Income Before Depreciation|Editas Corp - EV/EBITDA Multiple|SLN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR (ProQR) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization sangamo.com|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology)|EV/EBITDA Multiple MGX|Total Company Value to Operating Income Before Depreciation Ratio Precision BioSciences Inc.|EV/EBITDA Multiple GBIO (Generation Bio Co)|EV/EBITDA Multiple Boundless Bio, Inc BOLD|Exicure Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Imunon IMNN|PHIO: EV/EBITDA Multiple|MBIO: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics, Inc.|EV/EBITDA Multiple Bionano Genomics, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied DNA (APDN)|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc
